Navigation Links
Bioheart, Inc. Announces Results of Annual Meeting
Date:7/30/2008

the worldwide rights to the CE mark-approved POCKET(R) ECG beat-to-beat arrhythmia and A-Fib analysis monitoring system. According to industry data, arrhythmia and A-Fib analysis is one of the fastest growing segments in cardiology.

Additional Highlights:

-- MyoCell(R) Clinical Cell Therapy: Currently the subject of Bioheart's MARVEL Trial, a Phase II/III randomized, double-blind, placebo-controlled clinical trial, which involves 35 U.S. clinical sites, up from the five U.S. sites that participated in Bioheart's Phase I MYOHEART Trial. The trial is scheduled to enroll up to 330 patients and is the largest clinical trial of its kind ever undertaken.

-- Positive Clinical Results: Final clinical results of the Phase I MYOHEART Trial and Phase II-a SEISMIC Trial were presented at multiple major medical and scientific meetings this past year. In these studies, it was reported that 83 percent of patients treated with MyoCell(R) Therapy improved, or did not worsen, in the six-minute walk scores, while only 17 percent worsened. Additionally, in the SEISMIC Trial, 94 percent of patients treated with MyoCell(R) Therapy experienced improved or unchanged NYHA classification, while only six percent worsened. By comparison, 42 percent of the control group patients in the SEISMIC Trial, who received drug therapy alone, experienced a worsened NYHA classification. Both the six-minutes walk exercise test and quality of life scores are primary end points of MARVEL Trial.

-- MyoCell(R) SDF-1, intended to be an improvement of MyoCell(R) and being developed in collaboration with the University of Florida utilizing intellectual property licensed by the Cleveland Clinic, demonstrated positive functional improvement in two separate animal studies. Bioheart is preparing to enter into clinical registry studies in Switzerland and is working with the FDA on obtaining an IND for clinical trials in the U.S.

-- Bioheart TGI-1200(TM) System, a bedside apparatus f
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
2. Bioheart, Inc. Announces Financial Results for First Quarter 2008
3. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
4. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
5. Bioheart, Inc. to Transfer to Nasdaq Capital Market
6. Bioheart, Inc., Added to Russell Microcap Index
7. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
8. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
9. Bioheart, Inc., Announces Management Change
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... , May 23, 2013  Verenium Corporation (Nasdaq: ... on the development and commercialization of high-performance enzymes, today ... Financial Officer, will present at two upcoming conferences. ... will present at the Second Annual Marcum LLP Microcap ... Hyatt Hotel in New York City.  The presentation is ...
(Date:5/23/2013)... SynCardia Systems, Inc. ( http://www.syncardia.com ), manufacturer of ... CE (Europe) approved Total Artificial Heart, announced today that ... than 380,000 visitors annually, is featuring the SynCardia ... portable driver as part of its $3 million Bodyworks ... kind. , “BodyWorks combines the latest technology with ...
(Date:5/23/2013)... 2013 Bed bugs compromised Penn ... already confirmed it. Meanwhile, My Cleaning Products offered complimentary samples ... fight the pests without using harmful chemical elements. , ... 2013, the affected building was actually a dormitory , ... said made on May 13 and bed bug presence was ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... 10, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an ... and fight Human Immunodeficiency Virus (HIV) infections, today announced ... 30, 2011. GeoVax reported a net loss ... ended September 30, 2011, compared to $644,666 ($0.04 per ...
... Theravalues, a Japan based bio-venture, announced today ... prevention of heart failure and its progression for the ... started with the registration in July 2010, conducted by ... and University of Shizuoka, Japan, the researchers found that ...
... Research has expanded its research footprint to support ... offering high-quality biospecimens coupled with unprecedented premium data ... with AdeptBio, LLC ( http://www.adeptbio.com ).   ... services as needed to facilitate prospective collections of ...
Cached Biology Technology:GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 2GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 3GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 4GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results 5Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients 2ACORN Research, LLC Announces Partnership with AdeptBio, LLC 2
(Date:5/23/2013)... with autologous cord blood. Following a cardiac arrest with ... been in a persistent vegetative state with minimal ... the cord blood containing stem cells, the symptoms improved ... speak simple sentences and to move. "Our findings, along ... doubts about the effectiveness of the new therapy", says ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
(Date:5/23/2013)... Wis. In an age when microbial pathogens are ... tamp down infection, a team of Wisconsin scientists has ... curbing the bacteria that cause staph infections. , Writing ... Society , a group led by University of Wisconsin-Madison ... with the "quorum sensing" behavior of Staphylococcus aureus ...
Breaking Biology News(10 mins):First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2
... DC Cancer researchers at Georgetown University,s Lombardi Comprehensive ... they say shuts down growth of human glioblastoma tumors ... of brain cancers; there is no effective treatment. In ... researchers demonstrate how this antibody latches onto a receptor ...
... joined forces in a groundbreaking assessment of the status of ... fishery ecosystem scientist from the CSIRO Wealth from Oceans Flagship, ... report on a two-year study, led by US scientists Dr ... the University of Washington. The study shows that steps ...
... A new approach to windows that could let in ... to 99% in buildings in Tropical regions without losing ... the International Journal of Engineering Systems Modelling and ... in the School of Environment, Resources and Development, at ...
Cached Biology News:Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 2Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers 3Global curbs on overfishing are beginning to work 2Opening a new window on daylight 2
... O 2 S 2 Formula ... crystalline powder Assay: greater than or ... Melting Point: greater than or equal ... or equal to 1% Storage: ...
... Fluorescence Test Plate consists of an anodized ... Inert Organic Fluorescent Compounds embedded in polymerized ... on BioTeks FLx800 and Synergy Multi-Detection Readers. ... GLP compliance while reducing the need for ...
... The ICS-1500 system provides excellent ... dual-piston pumping, electrolytic suppression, and column ... instrument offers outstanding sensitivity and stability. ... quieter baselines for trace-level work. Operate ...
Anti-WT-1 Liquid. In 10 μM PBS, 0.2 % BSA, pH 7.6. Recognizes the ~47-55 kDa Wilm's tumor protein in Wilm's tumor tissue. ...
Biology Products: